Loading clinical trials...

TAILORx Tissue Bank | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

TAILORx Tissue Bank

Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)

NCT02050750•Cancer Trials Ireland

Summary

This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.

Detailed Description

The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance. The secondary objectives are: * To validate emerging signatures/biomarkers identified. * To develop new assays for the breast cancer clinic.

Eligibility

Age

18 - 75 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
•Patients with adequate tumor tissue available

Locations (12)

Bons Secours Hospital

Cork, Ireland

Cork University Hospital

Cork, Ireland

Letterkenny General Hospital

Donegal, Ireland

Adelaide and Meath National Children's Hospital Tallaght

Dublin, Ireland

St Vincent Universtiy Hospital

Dublin, Ireland

St James Hospital

Dublin, Ireland

Beaumont Hospital

Dublin, Ireland

Mater Misericordiae University Hospital

Dublin, Ireland

Galway University Hospital

Galway, Ireland

Midwestern Regional Hospital

Limerick, Ireland

Key Dates

Start Date

December 1, 2013

Primary Completion Date

December 1, 2020

Completion Date

November 1, 2031

Last Updated

December 19, 2025

Enrollment

600

ACTUAL participants

Conditions

Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TAILORx Tissue Bank

Inclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer